INSP (Inspire Medical Systems) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INSP Inspire Medical Systems Inc INSP
58 GF Score
Price $76.78
GF Value $189.84
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Inspire Medical Systems Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Inspire Medical Systems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.0 Mil. Inspire Medical Systems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $29.1 Mil. Inspire Medical Systems's annualized EBITDA for the quarter that ended in Jun. 2026 was $30.8 Mil. Inspire Medical Systems's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.94.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Inspire Medical Systems's Debt-to-EBITDA or its related term are showing as below:

INSP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.46   Med: -0.86   Max: 0.49
Current: 0.37

During the past 11 years, the highest Debt-to-EBITDA Ratio of Inspire Medical Systems was 0.49. The lowest was -1.46. And the median was -0.86.

INSP's Debt-to-EBITDA is ranked better than
76.86% of 471 companies
in the Medical Devices & Instruments industry
Industry Median: 1.64 vs INSP: 0.37

Inspire Medical Systems  (NYSE:INSP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Inspire Medical Systems Debt-to-EBITDA Related Terms


Inspire Medical Systems Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Inspire Medical Systems's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inspire Medical Systems Debt-to-EBITDA Chart

Inspire Medical Systems Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Inspire Medical Systems Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

INSP vs CNMD, TNDM, NVCR: Debt-to-EBITDA Comparison

For the Medical Devices subindustry, Inspire Medical Systems's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inspire Medical Systems Debt-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inspire Medical Systems's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Inspire Medical Systems's Debt-to-EBITDA falls into.


INSP
58GF Score
Inspire Medical Systems Inc INSP
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inspire Medical Systems Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Inspire Medical Systems's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.157 + 29.998) / 79.791
=0.40

Inspire Medical Systems's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 29.093) / 30.848
=0.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Inspire Medical Systems (INSP) Overvalued in 2026?

Based on GuruFocus' analysis, Inspire Medical Systems stock appears to be undervalued. The current stock price of $76.78 is trading 59.6% below its estimated GF Value™ of $189.84. GuruFocus considers Inspire Medical Systems to be Significantly Undervalued.

Key valuation signals for INSP:

  • Debt-to-EBITDA:
  • GF Value™: $189.84 vs. price of $76.78 (59.6% below fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the INSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inspire Medical Systems Business Description

Other Exchanges 2DR:Germany
Address 5500 Wayzata Boulevard, Suite 1600, Golden Valley, MN, USA, 55416
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
58GF Score

Get the complete analysis for INSP

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$76.78
Price
$189.84
GF Value